153 related articles for article (PubMed ID: 35396385)
1. A machine-learning based objective measure for ALS disease severity.
Vieira FG; Venugopalan S; Premasiri AS; McNally M; Jansen A; McCloskey K; Brenner MP; Perrin S
NPJ Digit Med; 2022 Apr; 5(1):45. PubMed ID: 35396385
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity and specificity of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised to detect dysarthria in individuals with amyotrophic lateral sclerosis.
Donohue C; Chapin JL; Anderson A; DiBiase L; Gray LT; Wymer JP; Plowman EK
Muscle Nerve; 2023 Sep; 68(3):296-302. PubMed ID: 37345346
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
4. Patient reported outcomes in ALS: characteristics of the self-entry ALS Functional Rating Scale-revised and the Activities-specific Balance Confidence Scale.
Chew S; Burke KM; Collins E; Church R; Paganoni S; Nicholson K; Babu S; Scalia JB; De Marchi F; Ellrodt AL; Moura LMVR; Chan J; Berry JD
Amyotroph Lateral Scler Frontotemporal Degener; 2021 Nov; 22(7-8):467-477. PubMed ID: 33771057
[No Abstract] [Full Text] [Related]
5. Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.
Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
Muscle Nerve; 2022 Nov; 66(5):593-602. PubMed ID: 36053970
[TBL] [Abstract][Full Text] [Related]
6. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
Muscle Nerve; 2022 Nov; 66(5):583-592. PubMed ID: 36054038
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
[TBL] [Abstract][Full Text] [Related]
8. Utility of the ALSFRS-R for predicting ALS and comorbid disease neuropathology: The Veterans Affairs Biorepository Brain Bank.
Colvin LE; Foster ZW; Stein TD; Thakore-James M; Salajegheh MK; Carr K; Spencer KR; Abdul Rauf N; Adams L; Averill JG; Walker SE; Robey I; Alvarez VE; Huber BR; McKee AC; Kowall NW; Brady CB
Muscle Nerve; 2022 Aug; 66(2):167-174. PubMed ID: 35585776
[TBL] [Abstract][Full Text] [Related]
9. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
10. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis.
Rooney J; Burke T; Vajda A; Heverin M; Hardiman O
J Neurol Neurosurg Psychiatry; 2017 May; 88(5):381-385. PubMed ID: 27888187
[TBL] [Abstract][Full Text] [Related]
11. Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19.
Brooks BR; Pioro EP; Katz J; Takahashi F; Takei K; Zhang J; Apple S
Muscle Nerve; 2022 Feb; 65(2):180-186. PubMed ID: 34816454
[TBL] [Abstract][Full Text] [Related]
12. Video-Based Facial Movement Analysis in the Assessment of Bulbar Amyotrophic Lateral Sclerosis: Clinical Validation.
Guarin DL; Taati B; Abrahao A; Zinman L; Yunusova Y
J Speech Lang Hear Res; 2022 Dec; 65(12):4667-4678. PubMed ID: 36367528
[TBL] [Abstract][Full Text] [Related]
13. Association between nutritional status and disease severity using the amyotrophic lateral sclerosis (ALS) functional rating scale in ALS patients.
Park Y; Park J; Kim Y; Baek H; Kim SH
Nutrition; 2015; 31(11-12):1362-7. PubMed ID: 26429656
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model.
Bakker LA; Schröder CD; van Es MA; Westers P; Visser-Meily JMA; van den Berg LH
J Neurol; 2017 Jul; 264(7):1413-1420. PubMed ID: 28608303
[TBL] [Abstract][Full Text] [Related]
15. Assessing upper limb function with ALSFRS-R in amyotrophic lateral sclerosis patients.
Pinto S; Gromicho M; de Carvalho M
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Aug; 20(5-6):445-448. PubMed ID: 31032642
[No Abstract] [Full Text] [Related]
16. Six-Minute Walk Test as a Measure of Walking Capacity in Ambulatory Individuals With Amyotrophic Lateral Sclerosis.
Sanjak M; Langford V; Holsten S; Rozario N; Patterson CGM; Bravver E; Bockenek WL; Brooks BR
Arch Phys Med Rehabil; 2017 Nov; 98(11):2301-2307. PubMed ID: 28465220
[TBL] [Abstract][Full Text] [Related]
17. Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients.
Ohta Y; Yamashita T; Nomura E; Hishikawa N; Ikegami K; Osakada Y; Matsumoto N; Kawahara Y; Yunoki T; Takahashi Y; Takamiya M; Tadokoro K; Sasaki R; Nakano Y; Tsunoda K; Sato K; Omote Y; Takemoto M; Abe K
J Neurol Sci; 2020 Aug; 415():116906. PubMed ID: 32446009
[TBL] [Abstract][Full Text] [Related]
18. ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale.
Maier A; Boentert M; Reilich P; Witzel S; Petri S; Großkreutz J; Metelmann M; Lingor P; Cordts I; Dorst J; Zeller D; Günther R; Hagenacker T; Grehl T; Spittel S; Schuster J; Ludolph A; Meyer T;
Neurol Res Pract; 2022 Dec; 4(1):60. PubMed ID: 36522775
[TBL] [Abstract][Full Text] [Related]
19. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).
Cedarbaum JM; Stambler N; Malta E; Fuller C; Hilt D; Thurmond B; Nakanishi A
J Neurol Sci; 1999 Oct; 169(1-2):13-21. PubMed ID: 10540002
[TBL] [Abstract][Full Text] [Related]
20. Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R.
Jackson C; De Carvalho M; Genge A; Heiman-Patterson T; Shefner JM; Wei J; Wolff AA
Amyotroph Lateral Scler Frontotemporal Degener; 2018 Nov; 19(7-8):506-512. PubMed ID: 30379086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
